Physician profile
Robert Henderson
NPI 1356552376
$6,730.25
in general payments reported to CMS, 2019-2025
30 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $1,171 · 2021: $1,288 · 2022: $1,169 · 2023: $788 · 2024: $766 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.46 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,539.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $969.41 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $565.61 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $473.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $401.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $329.80 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $277.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.77 | 2019-2025 | Jardiance |
| Pfizer INC. | $252.29 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $229.08 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $202.93 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.10 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $131.50 | 2019-2021 | |
| Astellas Pharma US INC | $130.09 | 2019-2025 | Veozah |
| Abbott Laboratories | $117.18 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.90 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.55 | 2022-2025 | Camzyos, Eliquis |
| Supernus Pharmaceuticals, INC. | $79.17 | 2019-2021 | |
| Dexcom, INC. | $74.33 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $64.27 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.01 | 2019-2022 | |
| Eisai INC. | $58.56 | 2020-2021 | |
| Sanofi Pasteur INC. | $37.66 | 2023-2024 | |
| Esperion Therapeutics, INC. | $35.34 | 2021-2024 | Nexletol |
| Axsome Therapeutics, INC. | $28.05 | 2025 | Auvelity |
| Exact Sciences Corporation | $18.48 | 2025 | The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $17.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2021 | |
| Medtronic, INC. | $15.18 | 2022 | |
| Biogen, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.